These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11053098)

  • 1. Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.
    Selmaj KW
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i94-102. PubMed ID: 11053098
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors.
    Selmaj KW; Raine CS
    Neurology; 1995 Jun; 45(6 Suppl 6):S44-9. PubMed ID: 7783912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB.
    Taoufik E; Tseveleki V; Chu SY; Tselios T; Karin M; Lassmann H; Szymkowski DE; Probert L
    Brain; 2011 Sep; 134(Pt 9):2722-35. PubMed ID: 21908876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
    Chang JT; Lichtenstein GR
    Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Ruuls SR; Sedgwick JD
    Immunol Cell Biol; 1998 Feb; 76(1):65-73. PubMed ID: 9553778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update.
    Davis MW; Feige U; Bendele AM; Martin SW; Edwards CK
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i41-3. PubMed ID: 11053086
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor and motoneuronal degeneration: an open problem.
    Ghezzi P; Mennini T
    Neuroimmunomodulation; 2001; 9(4):178-82. PubMed ID: 11847479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental autoimmune encephalomyelitis].
    Cornet A; Vizler C; Liblau R
    Rev Neurol (Paris); 1998 Sep; 154(8-9):586-91. PubMed ID: 9809373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.
    Edwards CK
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I73-81. PubMed ID: 10577978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/VLA-4.
    Selmaj K; Walczak A; Mycko M; Berkowicz T; Kohno T; Raine CS
    Eur J Immunol; 1998 Jun; 28(6):2035-44. PubMed ID: 9645385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement.
    Minden K; Aganna E; McDermott MF; Zink A
    Ann Rheum Dis; 2004 Oct; 63(10):1356-7. PubMed ID: 15361406
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumour necrosis factor is trafficked to a mitochondrial tumour necrosis factor binding protein.
    Ledgerwood EC; Prins JB; Bright NA; Johnson DR; Wolfreys K; Pober JS; O'Rahilly S; Bradley JR
    Biochem Soc Trans; 1998 Nov; 26(4):S316. PubMed ID: 10047830
    [No Abstract]   [Full Text] [Related]  

  • 13. [1/2 The anti-TNF alpha drugs].
    Medjoub M; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Oct; (719):59-61. PubMed ID: 18020248
    [No Abstract]   [Full Text] [Related]  

  • 14. A tumor necrosis factor receptor 1-dependent conversation between central nervous system-specific T cells and the central nervous system is required for inflammatory infiltration of the spinal cord.
    Gimenez MA; Sim J; Archambault AS; Klein RS; Russell JH
    Am J Pathol; 2006 Apr; 168(4):1200-9. PubMed ID: 16565495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.
    Zhang X; Hupperts R; De Baets M
    Immunol Res; 2003; 28(1):61-78. PubMed ID: 12947225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor.
    Su X; Zhou T; Yang P; Edwards CK; Mountz JD
    Arthritis Rheum; 1998 Jan; 41(1):139-49. PubMed ID: 9433879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists.
    Wildemann B; Rudofsky G; Kress B; Jarius S; Konig F; Schwenger V
    Neurology; 2007 May; 68(20):1742-4. PubMed ID: 17360963
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein ameliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression.
    Glabinski AR; Bielecki B; Kawczak JA; Tuohy VK; Selmaj K; Ransohoff RM
    Autoimmunity; 2004; 37(6-7):465-71. PubMed ID: 15621573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis.
    Trubiani O; Giacoppo S; Ballerini P; Diomede F; Piattelli A; Bramanti P; Mazzon E
    Stem Cell Res Ther; 2016 Jan; 7():1. PubMed ID: 26729060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?
    van Deventer SJ
    Gut; 2002 Sep; 51(3):362-3. PubMed ID: 12171957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.